The 3rd Annual Animal Models for Therapeutic Research
Improve the validity of your models at the industry's only multi-disciplinary animal models conference
With no other meetings currently catering for those working on in vivo research across diverse therapeutic areas and model systems, Informa Life Sciences’ Animal Models for Therapeutic Research conference returns for a third year.
Join us for a case-study packed programme presenting the latest developments, validation and application of in vivo models to enhance drug discovery and development from key academic research institutions and leading industry organisations, including AstraZeneca, Amgen, Sanofi-Aventis, Eli Lilly, MedImmune and many more....
Highlights of Animal Models for Therapeutic Research 2010
- Explore the latest techniques for humanisation of animal models read more
- Animal models for efficacy, safety and toxicology testing read more
- Discover innovative animal models of disease read more
- Techniques for obtaining data from animal tests read more
- Bringing together leading researchers from pharmaceutical, biotech and academic research institutes read more
Our 2010 expert speaker panel includes:
Our 2010 expert speaker panel includes:
Michael O'Neill, PhD
Senior Research Advisor
Eli Lilly & Co. Ltd, UK
|
Wim Bleeker
Director Translational Research & Pharmacology,
Genmab B.V.
|
- Thomas Kongstad Petersen, LEO Pharma, Denmark
- Jos Jonkers, Netherlands Cancer Institute, The Netherlands
- Olivier E. Bergis, Sanofi-Aventis Research & Development, France
- Rakesh Dixit, Ph.D., DABT, MedImmune, Gaithersburg, MD, USA
- Dr. Nicolau Beckmann, Novartis Institutes for BioMedical Research, Switzerland
- Joerg Heyer, PhD, AVEO Pharmaceuticals, Inc. USA
- Susan E. Browne, Ph.D. Merck Research Laboratories, West Point, PA, USA
- Dr Paul K Potter, Mary Lyon Centre, Medical Research Council Harwell, UK
Conference Sponsor
Sponsor
Promotional Participants
Media Partners
Co-located Events
Dates and Venues
08 Jun 2010 - 09 Jun 2010
Renaissance Koeln Hotel
This ‘must-attend’ conference is specifically tailored for all those working within in vivo research from pharmaceutical, biotech and academic research institutions:
Those who attended previously include:
- Senior Scientist
- Research Scientist
- Director Pharmacology
- Head of Non Clinical R&D Department
- Head of in vivo Imaging
- Pre-Clinical Research Department
- Group Leader In-Vivo Pharmacology
- Head of Pharmacology
- Chief Scientific Officer
- Scientific Director
7 June 2010: Pre- conference workshop
Effectively Deciding on your Animal Species for a Pre-Clinical Study
This one day interactive workshop will explore the ups and downs of drug development programmes and suggest that often we have preclinical assays of pharmacological activity and not disease models. This workshop will explore why we choose a particular species to use in our experiments. It will be a highly interactive session and will use an example of the development of Neurokinin-1 receptor antagonists as a case study.
Workshop leader: F David Tattersall, Director, Genitourinary Research Unit, Pfizer Group Research and Development, UK
Media Partners
Reviews
"Useful mixture of topics on current and future animal models, their role in therapeutical research, and some interesting case studies"
"An interesting and informative conference reviewing current techniques and enhancements in preclinical animal models"
8th June 2010: Evening seminar
Meet the Regulators: Successfully Gaining Regulatory Approval of Animal Models
This seminar will provide an opportunity to discuss with regulatory representatives the key issues surrounding animal models. Some of the issues being addressed will include:
• Developing alternative strategies for pre-clinical testing of monoclonal antibodies, what will/ will not be accepted by the regulators in terms of translatability to clinical trials
• Regulatory opinion and acceptance of humanisation strategies for antibody safety
testing as an alternative to non human primate models and drug development
• How the agencies accept use of transgenic mice models for long term studies
• Regulatory requirements for the identification and use of novel biomarkers in drug development
• Update on the information requirement for bio similar model development
Seminar Leaders:
Christian Steffen, MD, Director and Professor, Head of Clinical Trials, BfArM, Germany
Dr. Elke Stahl, Preclinical Assessor, BfArM, Germany
